SCHEDULE: Alta Partners Discloses 5.17% Stake in AEON Biopharma

Alta Partners LLC has disclosed a beneficial ownership of 5.17% of AEON Biopharma, Inc.'s common stock, totaling 586,335 shares.

Summary

• Alta Partners LLC reported beneficial ownership of 586,335 shares of AEON Biopharma, Inc. common stock.
• This stake represents 5.17% of the total class of securities.
• Alta Partners LLC holds sole voting power and sole dispositive power over all 586,335 shares.
• The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934.
• The event requiring this filing occurred on June 30, 2025.

Sentiment

Score: 6

Explanation: The filing discloses a new significant beneficial ownership stake by Alta Partners LLC in AEON Biopharma, Inc., which can be interpreted as a positive signal of investor interest, although the document itself is a factual ownership disclosure and does not contain performance or operational sentiment.

Positives

• Disclosure of a new significant institutional investor, Alta Partners LLC, holding over 5% of AEON Biopharma, Inc. common stock.
• Alta Partners LLC holds sole voting and dispositive power over its 586,335 shares, indicating direct control over its stake.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor holding 5.17% of common stock may influence market perception and potentially share price.

Key Dates

Keywords

AEON Biopharma Inc., Alta Partners LLC, Beneficial Ownership, Schedule 13G, Common Stock, SEC Filing, Institutional Investor, Equity Stake, Biopharma